An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
This treatment has been approved for sale to the public.
First Posted: November 15, 2010
Last Update Posted: May 22, 2015
Information provided by (Responsible Party):